SCHEDULE: MAK Capital Urges Evotec to Spin Off Just Biologics

Activist investor MAK Capital, holding a 7% stake in Evotec SE, is pushing for a U.S. IPO of Just Biologics and accelerated restructuring to unlock shareholder value.

Summary

• MAK Capital Fund LP has disclosed a 7% beneficial ownership stake in Evotec SE.
• The investor is demanding a carve-out and U.S. IPO of the 'Just Biologics' (JEB) platform, arguing it is undervalued within the parent company.
• MAK Capital criticizes the current 'Horizon' restructuring plan as too slow, with margin expansion not expected until 2027 or later.
• The investor proposes the appointment of Dr. Wolfgang Hofmann to the Supervisory Board to improve oversight and strategic direction.
• MAK Capital highlights a 90% decline in Evotec's share price over the past five years as evidence of management's failure to execute.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly critical intervention by a major shareholder, signaling deep dissatisfaction with current management's pace and strategic direction.

Positives

• Just Biologics (JEB) shows strong growth, with non-Sandoz/non-DoD revenue increasing over 100% through September 2025.
• The Sandoz transaction provides clear market validation for the JEB platform's technology.
• MAK Capital brings a track record of outperforming the S&P 500 by approximately 1,000% net of fees over 25 years.
• The company possesses high-value assets that are currently obscured by a struggling drug discovery segment.

Negatives

• Evotec's share price has declined by approximately 90% over the last five years.
• The current management's restructuring timeline is viewed as 'lackadaisical' and risks further deterioration of the business.
• The market reacted negatively to the 'Horizon' transformation plan with a 17% decline over two days.
• Management has reportedly dismissed the investor's proposal to appoint a new, independent board member.

Risks

• Continued erosion of shareholder confidence due to slow execution of the restructuring plan.
• Potential loss of key talent and development partners if the restructuring remains elongated.
• The risk of a contested board election if the company refuses to nominate the investor's preferred candidate.
• The drug discovery business continues to struggle, potentially dragging down the valuation of the entire group.

Future Outlook

The investor expects the company to compress its restructuring timeline, frontload site consolidation, and deliver tangible operating improvements by the second half of 2026, while pursuing a U.S. IPO for the Just Biologics unit.

Management Comments

• We believe the Company's shares are materially undervalued.
• Corrective actions have not been employed with requisite urgency.
• The lackadaisical pace of the restructuring plan further erodes shareholder confidence.
• We are fully prepared to exercise our shareholder rights and put Dr. Hofmann up as an alternative candidate.

Industry Context

StockSavvy.ai notes that this move reflects a broader trend of activist investors targeting European biotech firms that have failed to capitalize on high-growth sub-segments, specifically those with U.S.-based manufacturing assets that command higher valuation multiples than traditional European drug discovery services.

Comparison to Industry Standards

• Comparable biologics CDMO and manufacturing technology companies typically trade at 5x revenue or higher.
• Evotec's current valuation is being compared unfavorably to pure-play U.S. biologics manufacturing peers.
• The proposed restructuring timeline is being compared against industry benchmarks for rapid turnaround success.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant value unlocking via spin-off.
• Employees: Potential for restructuring-related workforce actions.
• Management: Increased pressure to accelerate operational changes or face board challenges.

Next Steps

• Request for a meeting between MAK Capital and the Chairpersons of the Supervisory and Management Boards.
• Potential nomination of Dr. Wolfgang Hofmann as an alternative candidate for the Supervisory Board.
• Potential exercise of shareholder rights to force a vote on board composition.

Key Dates

Recommendation

The stock is currently in a state of transition with significant activist pressure. While the potential for a spin-off could unlock value, the execution risk and management's current resistance suggest a 'hold' until there is clarity on whether the board will adopt the investor's proposals.

Keywords

Evotec, MAK Capital, Just Biologics, Activist Investor, Biotech, Restructuring, IPO, Shareholder Value